RCS - ValiRx PLC - Investor Webinar

ValiRxAnnouncement

01/03/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA4165Ra&default-theme=true

RNS Number : 4165R  ValiRx PLC  01 March 2023

1 March 2023

 

 

ValiRx PLC ("ValiRx" or the "Company")

Investor Webinar

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health announces that Dr Suzanne
Dilly will be presenting a live investor webinar on Wednesday, 8 March 2023 at
17:30 GMT.

The presentation will concentrate on the Company's strategy for its new tCRO
operations, including progress on setting up the dedicated lab facilities in
Nottingham.

The live webinar, which will be hosted by the Company's Joint Broker, Turner
Pope Investments, is open to existing and prospective investors. There will be
a Q&A session for investors after the presentation and questions can be
submitted pre-event as part of the registration process. In addition,
questions can be submitted during the live event.

To register for the webinar please visit the following link:

https://vimeo.com/webinars/events/d731558a-ecb5-40f0-9d7b-415902d2dd1f
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fvimeo.com%2Fwebinars%2Fevents%2Fd731558a-ecb5-40f0-9d7b-415902d2dd1f&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C93c795a88af6490e65cf08db18a8d613%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638130885649460080%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=3BeR1H5dsXqlj%2BvHk%2FduFtZHz7yO6xNTPVhcxOF7cbg%3D&reserved=0)

The Directors of the Company take responsibility for this announcement.

For further information, please contact:

 

 ValiRx plc                                            Tel: +44 (0) 2476 796496

 Dr Suzanne Dilly, CEO                                 www.valirx.com (http://www.valirx.com/)

                                                       Suzanne.Dilly@valirx.com
 V Formation (Public Relations)                        +44 (0) 115 787 0206

                                                       www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive                    lucy@vformation.biz

 Sue Carr - Director                                   sue@vformation.biz
 Cenkos Securities Limited (Joint Broker)              Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (TPI) Limited (Joint Broker)  Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADGGDDSGDDGXI